Increasing prevalence of chronic pain conditions globally coupled with growing awareness towards the effectiveness of oxycodone drugs in pain management is expected to drive the growth of the oxycodone drugs market. Moreover, the rising geriatric population worldwide, who are more prone to chronic pain issues, is also anticipated to fuel market growth.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Product Type, Distribution Channel |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Teva Pharmaceutical Industries, Endo Pharmaceuticals Inc, Collegium Pharmaceutical Inc, Mallinckrodt Pharmaceuticals, Sun Pharmaceutical Industries |
Strict regulatory guidelines regarding the prescription and usage of oxycodone drugs, particularly due to their high potential for abuse and addiction, is expected to be a major restraint for the market. Additionally, the increasing availability and preference for alternative pain management therapies such as non-pharmacological treatments and holistic approaches could pose a challenge to the growth of the oxycodone drugs market.